Metasystemic Plan for Curing Cancer Introduction Cancer is not a single disease but a family of disorders characterized by genomic instability , loss of growth control, metabolic rewiring, immune evasion, angiogenesis, tissue invasion and metastasis. A curative strategy must address heterogeneity of tumor cells , the supportive tumor microenvironment , the systemic milieu (immune, metabolic and microbiome), and the patient’s lifestyle and psychosocial health . Traditional treatments (surgery, chemotherapy, radiotherapy) have improved survival for many cancers, but relapse and metastasis remain common. A metasystemic cure therefore integrates multi‑scale interventions – molecular, cellular, organ‑level and systemic – with cross‑cultural and historical therapies. 1. Metasystemic Obstacles to Cure Genomic diversity and driver mutations – Tumors acquire mutations, chromosomal rearrangements and epigenetic alterations that drive uncontrolled growth, resistance and metastasis. Many cancers harbor multiple driver genes or evolve sub‑clones. Immune evasion and suppressive microenvironment – Cancer cells up‑regulate PD‑L1 and other checkpoints, recruit regulatory T cells (Tregs) and myeloid‑derived suppressor cells, and create hypoxic, acidic niches that impair immune cell function. Fasting studies show that natural killer (NK) cells reprogram to use lipids when fasting, increasing survival in lipid‑rich tumors; mice fasted 24 hours twice a week produced NK cells that metabolically adapted to fatty acids and produced more interferon‑γ, enhancing anti‑tumor activity Metabolic reprogramming – Tumors shift from oxidative phosphorylation to aerobic glycolysis (Warburg effect), increase glutamine dependency and exploit lipid metabolism. The microenvironment is nutrient‑poor and lipid‑rich, which suppresses immune cells; NK cells adapt through fasting to exploit fatty acids and produce anti‑tumor cytokines Angiogenesis and hypoxia – Solid tumors secrete VEGF and remodel extracellular matrix (ECM) to develop chaotic vasculature. Hypoxia induces further angiogenesis and confers resistance to therapy. Hyperbaric oxygen (HBO) therapy can deplete dense ECM and enhance accumulation of engineered bacteria in tumors; in a preclinical study HBO increased intratumoral delivery of E. coli carrying photothermal agents, promoting immunogenic cell death and immune infiltration Chronic inflammation and systemic dysbiosis – Tumors exploit inflammatory cytokines (IL‑6, IL‑8) and neutrophil extracellular traps (NETs) to grow and metastasize. The gut microbiota influences systemic immunity and treatment response. Organ‑specific damage and lack of regeneration – Cytotoxic therapies damage bone marrow, gut mucosa, heart and other organs. Regeneration and tissue remodeling are essential for durable recovery. Patient factors – Lifestyle (diet, activity, sleep, stress) and comorbidities shape the systemic terrain. Exercise improves survival across major cancers; in a 2025 meta‑analysis, physically active breast‑cancer patients had 36 % lower all‑cause mortality (hazard ratio 0.64, 95 % CI 0.59– 0.70) and 31 % lower breast‑cancer‑specific mortality (HR 0.69) . Similar benefits were observed in lung cancer; physical activity reduced all‑cause mortality by 22 % and lung‑cancer‑specific mortality by 24 % 1. 2. 1 3. 2 4. 3 5. 6. 7. 4 5 1 2. Global Solutions: Modern and Traditional Therapies 2.1 Targeted and Gene‑Editing Therapies Precision drugs and antibody–drug conjugates – 2025 FDA approvals included targeted agents such as datopotamab deruxtecan (TROP‑2‑directed antibody–drug conjugate), avutometinib + defactinib (RAS pathway blockade) and telisotuzumab vedotin for c‑MET‑positive lung cancer . These drugs exemplify biomarker‑guided therapy. CRISPR‑edited T cells – A 2025 clinical trial modified tumor‑infiltrating lymphocytes by knocking out the CISH gene; modified T cells persisted, were safe and mediated durable disease control, including one complete response lasting over two years . Allogeneic CRISPR‑edited CAR‑T cells are being developed to provide off‑the‑shelf therapy; early trials show partial responses in solid tumors, but conditioning regimens cause severe side effects Oncolytic viruses and bacteria – Oncolytic viruses exploit tumor specificity and stimulate immunity. CLD‑201 uses stem cells loaded with vaccinia virus to deliver virus to tumors and turn “cold” tumors “hot” . Pelareorep replicates in cancer cells and activates interferons and tumor‑infiltrating lymphocytes . Cretostimogene grenadenorepvec achieved complete responses in bladder cancer trials . Hyperbaric oxygen enhances tumor penetration of bacteria‑based therapies . Oncolytic bacteria such as Clostridium novyi‑NT directly lyse tumor cells and stimulate immunity Prime editing and gene correction – Although not yet in clinical oncology, prime editing offers potential to correct oncogenic driver mutations with minimal off‑target effects. Development is underway for other diseases; the technology may eventually replace mutated oncogenes. 2.2 Immunotherapies and Biological Modulators Checkpoint inhibitors and bispecific antibodies – Bispecific antibodies have two binding sites; as of May 2025, seventeen bispecific antibodies are approved, offering dual engagement of tumor antigens and immune cells . Combination strategies with checkpoint inhibitors (PD‑1/ PD‑L1, CTLA‑4) remain central. Fasting and metabolic conditioning – Periodic fasting (24 hours twice a week) reprograms NK cells to use fatty acids, enabling them to survive in lipid‑rich tumors and produce more interferon‑γ . Fasting may thus augment immunotherapies. Ketogenic metabolic therapy – Glioblastoma cells rely on glycolysis; a small 2024 study showed that patients adhering to a ketogenic diet for >6 months had a 66.7 % three‑year survival compared with 8.3 % among non‑adherent patients (p = 0.0114) . Combining a high‑fat ketogenic diet with eFT508 (eIF4E inhibitor) starved pancreatic tumors and shrank them in mice High‑dose vitamin C – A randomized phase II trial in metastatic pancreatic cancer showed that adding intravenous high‑dose vitamin C to standard chemotherapy doubled median survival from eight months to 16 months ; progression‑free survival also improved (six vs. four months) . Patients experienced fewer side effects and improved quality of life Metformin and metabolic inhibitors – Meta‑analyses suggest metformin reduces overall cancer risk (RR 0.72) and lowers breast and colorectal cancer risk . Metformin activates AMPK, inhibits mTOR and reduces insulin/IGF‑1 signalling Vascular normalization and hyperbaric oxygen – Low‑dose anti‑angiogenic therapy normalizes chaotic tumor vessels, improving drug delivery. Hyperbaric oxygen depletes ECM and enhances delivery of engineered bacteria • 6 • 7 8 9 • 10 11 12 3 13 • • 14 • 1 • 15 16 • 17 18 19 • 20 21 • 3 2 2.3 Traditional and Ethnomedicinal Approaches Traditional Chinese Medicine (TCM) TCM aims to rebalance Yin–Yang , strengthen Qi and remove pathogenic factors. Many formulas have multi‑target effects: - Berberine (from Coptis chinensis ) induces apoptosis and inhibits migration of gastric cancer cells . - Andrographolide binds BAX, enhances apoptosis and reverses 5‑FU resistance - Triptolide and saikosaponin A modulate p53/p21 and Akt/mTOR pathways, promoting senescence and inhibiting metastasis . - Baicalein (from Scutellaria ) activates AMPK and inhibits lung tumor growth - She medicine herbs like Schisandra chinensis , Scutellaria baicalensis , Panax notoginseng , Lonicera japonica , Ganoderma lucidum and Hedyotis diffusa induce apoptosis, inhibit angiogenesis, enhance immunity and provide antioxidant effects . - Fu‑Zheng‑Qu‑Xie decoction (FZQX) – Chinese studies suggest FZQX improves immune function and survival in early‑stage lung cancer; however, data remain limited. Ayurveda and Rasayana Ayurveda treats cancer as a result of dosha imbalance (Vata–Pitta–Kapha) and uses Rasayana therapy to restore equilibrium. Herbs like Ashwagandha, Guduchi, Amalaki and Triphala provide immunomodulation and detoxification Curcumin , a component of turmeric, modulates NF‑κB, STAT3 and PI3K/Akt pathways to suppress proliferation, induce apoptosis and inhibit angiogenesis African and Indigenous Plants A 2024 review documented 105 plant species used to manage cancer in East Africa; leaves are the most common plant part and decoctions the main preparation . The region has over 6,000 potential anticancer plants, reflecting reliance on ethnomedicine due to limited access to conventional care Examples include Prunus africana , Warburgia salutaris , and Hypoxis hemerocallidea , which contain phytochemicals with cytotoxic and antioxidant properties. 3. Treatment Plan: The Ecosystem Reset for Cancer Drawing on these diverse interventions, we propose a four‑phase metasystemic protocol analogous to an “ecosystem reset” that addresses the hallmarks of cancer and integrates global therapies. Phase 1: Terrain Preparation and Inflammatory Reset Anti‑inflammatory and detoxification diet – Adopt a Mediterranean‑style or plant‑forward ketogenic diet emphasizing vegetables, healthy fats (olive oil, omega‑3s) and limited processed carbohydrates. This reduces insulin/IGF‑1 signalling and chronic inflammation, sets the stage for metabolic therapy, and may complement drugs such as metformin. Periodic fasting or fasting‑mimicking diets – Short fasting cycles reprogram NK cells to use fatty acids and increase interferon‑γ production, improving anti‑tumor immunity . Fasting protocols must be personalized to avoid malnutrition. Physical activity and stress reduction – Encourage moderate exercise (e.g., 150 minutes/week) and mind–body practices (yoga, Tai Chi). Exercise reduces all‑cause and cancer‑specific mortality in breast and lung cancers , enhances insulin sensitivity and stimulates immune function. Microbiome optimization – Implement prebiotic fiber, probiotics or fermented foods to restore gut diversity. Consider fecal microbiota transplantation for patients with dysbiosis (e.g., after antibiotics or chemotherapy). Monitor for bacterial endotoxins that drive inflammation. 22 23 24 25 26 27 28 29 30 1. 2. 1 3. 4 5 4. 3 Herbal detoxification and immunomodulation – Use TCM formulas (e.g., Hozai formulas such as Juzentaihoto) and Ayurvedic Rasayana herbs (Ashwagandha, Triphala). These herbs reduce inflammation, modulate immunity and support liver detoxification Phase 2: Immune Re‑education and Microenvironment Modulation Checkpoint inhibitors & bispecific antibodies – Use modern immunotherapies tailored to tumor antigen profile; combine with fasting and ketogenic therapy to enhance T cell infiltration and reduce glucose competition. Vaccines and oncolytic agents – Administer oncolytic viruses (e.g., vaccinia‑based CLD‑201) or bacteria (e.g., Salmonella , Clostridium novyi‑NT ) to lyse tumor cells and release antigens. Hyperbaric oxygen may enhance delivery and ECM penetration Phytochemicals targeting checkpoints and metabolism – Combine immune therapy with compounds like curcumin, berberine and andrographolide that modulate NF‑κB and PI3K/Akt pathways Microvascular normalization – Low‑dose anti‑angiogenic therapy to normalize tumor vessels; incorporate exercise and hyperbaric oxygen to improve perfusion. Stress and circadian alignment – Monitor heart‑rate variability, sleep quality and stress biomarkers; maintain circadian rhythm to support immune surveillance and metabolic health. Phase 3: Targeted Eradication and Genetic Correction Combination targeted therapy – Utilize antibody–drug conjugates, small‑molecule inhibitors (e.g., kinase inhibitors), and bispecific antibodies based on tumor genomics. For example, datopotamab deruxtecan (TROP‑2–directed) and telisotuzumab vedotin (c‑MET–directed) provide potent targeted cytotoxicity CRISPR‑edited cell therapies – Harvest patient T cells or NK cells, edit genes (CISH, TCRs) to enhance tumor recognition, and reinfuse them. Trials of CRISPR‑edited TILs have demonstrated safety and complete responses High‑dose vitamin C and metabolic adjuvants – Add intravenous vitamin C to chemotherapy to improve survival in pancreatic cancer (doubling median survival from 8 to 16 months) and extend progression‑free survival . Combine with metformin or AMPK activators to further disrupt tumor metabolism. Gene editing for oncogenic drivers – Develop prime editing or base editing to correct mutations in oncogenes (e.g., KRAS G12D, EGFR), delivered via safe viral or nanoparticle vectors. Although currently preclinical, this will be crucial for durable cures. Localized therapy – Implement targeted radiation, photothermal therapy (e.g., with bacteria carrying photothermal agents), and nanomedicine (e.g., liposomal curcumin) to eradicate residual disease. Phase 4: Regeneration and Adaptive Integration Regenerative medicine – Employ stem-cell–derived tissues or organoids to restore organ function after tumor resection or chemotherapy. For example, mesenchymal stem cells can modulate inflammation and promote regeneration, while engineered allogeneic microglia may replace dysfunctional immune cells. Reconstruction of immune/microbiome equilibrium – Continue probiotic and prebiotic interventions; consider phage therapy to selectively target pathogenic bacteria and control bacterially driven inflammation. Lifestyle maintenance and digital guardians – Use wearable sensors to track heart‑rate variability, activity, sleep and stress. AI‑driven platforms can provide real‑time feedback to optimize nutrition, exercise and stress reduction. 5. 31 27 1. 2. 3 3. 22 32 4. 5. 1. 6 2. 7 3. 17 18 4. 5. 1. 2. 3. 4 Long‑term surveillance – Monitor circulating tumor DNA, metabolic biomarkers and immune cell profiles. Early detection of recurrence enables prompt intervention. 4. Future Directions and Considerations Individualization – Each patient’s tumor has a unique genomic and immunologic landscape; integrate whole‑genome sequencing, transcriptomics and microbiome profiling to tailor therapy. Equity and access – Many advanced therapies are expensive; integrating cost‑effective interventions like exercise, fasting, herbal medicines and high‑dose vitamin C can improve outcomes worldwide. Research on under‑studied plants and traditions – East African and other indigenous plant medicines remain underutilized. Documenting and rigorously testing these remedies could yield new lead compounds Combination and sequencing – The order of interventions matters; metabolic conditioning and immune activation should precede targeted eradication, followed by regeneration. Systems biology models and clinical trials are needed to refine timing. Conclusion A cure for cancer cannot hinge on a single therapy; it requires orchestrating multiple interventions that collectively reprogram the tumor, the microenvironment and the whole‑body ecosystem. By combining modern precision medicine (gene‑editing, targeted drugs, immunotherapies), metabolic and lifestyle interventions (diet, fasting, exercise), traditional herbal wisdom (TCM, Ayurveda, African ethnobotany), and regenerative medicine , we can design a sequenced, adaptive plan to eradicate tumors, rebuild healthy tissues and maintain long‑term health. Continuous research, cross‑cultural collaboration and personalized application will be essential to transform this metasystemic vision into a reality. Fasting supercharges the cancer-killing properties of immune cells https://newatlas.com/medical/fasting-natural-killer-cells-cancer/ Hyperbaric oxygen enhances tumor penetration and accumulation of engineered bacteria for synergistic photothermal immunotherapy | Nature Communications https://www.nature.com/articles/s41467-024-49156-6 Exercise and survival benefit in cancer patients: evidence from a comprehensive meta-analysis - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12181474/ Transforming Cancer Therapy: Insights from 2025 H1 FDA Approvals and Preclinical Drug Discovery https://blog.crownbio.com/transforming-cancer-therapy-insights-from-2025-h1-fda-approvals-and-preclinical-drug-discovery New gene-editing therapy shows early success in fighting advanced GI cancers | Medical School https://med.umn.edu/news/new-gene-editing-therapy-shows-early-success-fighting-advanced-gi-cancers CRISPR Clinical Trials: A 2025 Update - Innovative Genomics Institute (IGI) https://innovativegenomics.org/news/crispr-clinical-trials-2025/ Oncolytic virus therapy for cancer: what’s been going on in 2025? https://www.labiotech.eu/in-depth/oncolytic-virus-therapy-cancer-2025/ Oncolytic bacteria: A revolutionary approach to cancer therapy - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12163578/ 4. 1. 2. 3. 29 30 4. 1 2 3 4 5 6 7 8 9 10 11 12 13 5 Bispecific antibodies: unleashing a new era in oncology treatment - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12320366/ Frontiers | Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1489812/full A Ketogenic Diet Could Improve the Response to Pancreatic Cancer Therapy | UC San Francisco https://www.ucsf.edu/news/2024/08/428251/ketogenic-diet-could-improve-response-pancreatic-cancer-therapy High-dose IV vitamin C plus chemotherapy doubles survival in advanced pancreatic cancer | Carver College of Medicine - The University of Iowa https://medicine.uiowa.edu/news/2024/11/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic- cancer Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12194869/ Tailoring traditional Chinese medicine in cancer therapy - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11749133/ Frontiers | The anticancer activity and mechanisms of She medicine herbs https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1610301/full Frontiers | A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeutics https://www.frontiersin.org/journals/natural-products/articles/10.3389/fntpr.2025.1635197/full Review of Herbal Medicinal Plants Used in the Management of Cancers in the East Africa Region from 2019 to 2023 - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10916491/ 14 15 16 17 18 19 20 21 22 23 24 25 31 32 26 27 28 29 30 6